Jim Cramer Reports That Eli Lilly and Company (LLY)'s Donanemab Was Approved in Japan For Treating Early Symptomatic Alzheimer's Disease

Jim Cramer shared early investment experiences and the importance of starting young in the stock market. Eli Lilly & Company (LLY) stands out for its strong financial performance and innovative drug lineup, making it a promising investment choice.